At the IGTP TODAY
In a recent collaborative work, led by researchers from IDIBELL-ICO (ProCURE, Oncobell programs), IDIAP Jordi Gol and GCAT (Genomes of Life, IGTP), the main diseases and associations that contribute significantly to the appearance of multimorbidity are identified. The study also points out inherited genetic factors that have an influence on the appearance of multimorbidity
Pere-Joan Cardona is a physician specialized in microbiology and parasitology and leader of the Experimental Tuberculosis Unit, which has been researching tuberculosis for 20 years at the Germans Trias i Pujol Research Institute (IGTP). Cardona was sworn in as full academician of the Royal European Academy of Doctors (RAED) on Tuesday in a ceremony in the auditorium at Fomento de Trabajo Nacional in Barcelona. Emili Gironella Masgrau made the formal proposal speech.
Researchers have developed a new non-invasive probe to detect the presence of metallic stents and monitor their potential structural failures in models of coronary artery disease. The new probe, which has been successfully tested on a murine model, would enable the substitution of surgical controls in patients with stents with a simple outpatient procedure. The study results from a collaboration between researchers from the Germans Trias i Pujol Research Institute (IGTP), the University of Barcelona (UB) and Universitat Politècnica de Catalunya (UPC).
Biointaxis, the new spin-off company of the IGTP, was recently constituted. The company stems from research led by Dr Antoni Matilla-Dueñas together with Dr Ivelisse Sánchez of the Neurogenetics Group of the IGTP and has been created to increase translational research leading to treatments and new genomic technologies for rare neurological diseases with genetic causes. The first project the company is undertaking is the development of a gene therapy for Friedreich's Ataxia.
Dr Daniel Fuster of the Addiction Unit of the Internal Medicine Service at the Germans Trias i Pujol University Hospital and Research Institute (IGTP) and the Universitat Autònoma de Barcelona has co-authored a landmark review article on alcohol use in patients with chronic liver disease with Dr Jeffrey H Samet of Boston Medical Center and University School of Medicine. The article has been published in the New England Journal of Medicine.
The Hereditary Cancer Research Group at the IGTP studies the genetic diseases that bring a high risk of developing cancer, one of which is neurofibromatosis (NF). The group has just started two new projects to study neurofibromatosis types 1 and 2 thanks to the support of the Neurofibromatosis Project Foundation.
Researchers at the Biomedical Research Institute of Lleida (IRBLleida), the Germans Trias i Pujol Research Institute (IGTP) and the Spanish Networked Group CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM) have shown that adult patients with diabetes type 1 (DT1) have healthier eating habits and stick closer to the Mediterranean diet than non-diabetic subjects.It has been published in the European Journal of Nutrition and is the first study that tracks the adherence to the Mediterranean diet in this type of patient.A study has also evaluated the positive benefits of exercise for people with diabetes type 1.
Researchers of the Cardiovascular Disease Group and the CIBERCV Group, led by Dr Antoni Bayés Genís, have advanced the study of prognostic markers for heart failure, a progressive disease and a public health problem of the first order. They have studied monocyte (a type of white blood cell) count and distribution in a cohort of 400 outpatients with heart failure with a view to showing their predictive value. The study has been published in PLoS One.
A novel study indicates promising avenues in an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study indicates the possibility of using small vesicles (or exosomes) secreted by immature red blood cells as a vaccine platform against malaria. The paper was published in the journal Scientific Reports.
A team of researchers from the Germans Trias i Pujol Hospital and Institute on the Can Ruti Campus, have started a phase I trial to slow the progress of multiple sclerosis (MS) with a cell product that uses the patient's own cells and reprograms their immune system.
